Arkolith/Insider Trading/AGLE/Form 4

Turtle Cameron

Chief Executive Officer, DirectorSpyre Therapeutics, Inc. (AGLE) · full profile →Form 4 · filed Nov 27, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 24, 2023Conversion(C)723K—$0747K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 24, 2023Conversion(C)18K—$00
Nov 22, 2023Grant(A)374K—$0374K

Transaction Codes

C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-066131) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML